Facts and Hopes in Colorectal Cancer Immunotherapy

Area of Science:

• Oncology
• Immunology
• Cancer Research

Background:

• Colorectal cancers (CRCs) largely exist in a tolerogenic microenvironment, showing low immunogenicity and poor response to immunotherapy, particularly mismatch repair-proficient (pMMR) tumors.
• Current strategies combining immune checkpoint inhibitors (ICIs) with chemotherapy have largely failed in pMMR CRCs.
• While some studies suggest benefits of combining checkpoint blockade with radiation or tyrosine kinase inhibitors, these findings require validation in randomized trials.

Purpose of the Study:

• To review the challenges and emerging strategies in immunotherapy for colorectal cancer, focusing on mismatch repair-proficient tumors.
• To highlight the potential of next-generation immunotherapies and translational research in overcoming treatment resistance.

Main Methods:

• Review of current literature on colorectal cancer immunology and immunotherapy.
• Analysis of treatment outcomes for various immunotherapy combinations.
• Discussion of emerging therapeutic modalities and biomarker research.

Main Results:

• Mismatch repair-deficient (dMMR) CRCs are a minority and sensitive to ICIs, unlike the majority of pMMR CRCs.
• Combination therapies (ICIs + chemotherapy, radiation, or TKIs) have shown limited success or require further validation in pMMR CRCs.
• Next-generation therapies including engineered ICIs, bispecific T-cell engagers, and CAR-T cells show potential for improved tumor immunorecognition.

Conclusions:

• Significant advancements are needed to improve immunotherapy response in the majority of colorectal cancer patients with pMMR tumors.
• Identifying predictive biomarkers and developing combination strategies that amplify immune responses are crucial.
• Emerging engineered immunotherapies hold promise for a new era of effective colorectal cancer treatment.